PTC (NASDAQ:PTC – Get Free Report) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating ...
Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) have been given an average recommendation of “Moderate Buy” ...
StockStory.org on MSN5d
Reflecting On Design Software Stocks’ Q4 Earnings: PTC (NASDAQ:PTC)Looking back on design software stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including PTC ...
StockStory.org on MSN7d
PTC (PTC): Buy, Sell, or Hold Post Q4 Earnings?PTC has been in a holding pattern, posting a small loss of 4.7% while floating around $160.81. The stock also fell short of ...
Sometimes, the headline numbers don't tell the whole story. That's definitely the case with industrial software company PTC ...
It has been about a month since the last earnings report for PTC Inc. (PTC). Shares have lost about 6.4% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...
Proficio Capital Partners LLC purchased a new position in shares of PTC Inc. (NASDAQ:PTC – Free Report) in the fourth quarter, HoldingsChannel reports. The fund purchased 48,174 shares of the ...
PTC (NasdaqGS:PTC) experienced a 4.52% decline in its total shareholder returns over the past week, coinciding with the appointment of Trac Pham to its Board of Directors. Pham brings a strong record ...
PTC Therapeutics (NASDAQ:PTCT – Get Free Report) had its target price upped by research analysts at JPMorgan Chase & Co. from $72.00 to $78.00 in a research report issued to clients and investors on ...
Fintel reports that on March 11, 2025, B of A Securities upgraded their outlook for PTC Therapeutics (NasdaqGS:PTCT) from Underperform to Neutral. As of March 5, 2025, the average one-year price ...
Calumet (NASDAQ:CLMT) +10.2% in Monday's trading as UBS raised the maker of hydrocarbon products to Neutral from Sell with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results